-
公开(公告)号：EP1121133A1
公开(公告)日：2001-08-08
申请号：EP99951948.1
申请日：1999-10-12
发明人： HARADA, Shun-Ichi , MACHWATE, Mohamed , RODAN, Gideon, A. , WEINREB, Miron , LABELLE, Marc , METTERS, Kathleen , YOUNG, Robert, N.
CPC分类号： A61K31/663 , A61K31/00 , A61K31/192 , A61K31/20 , A61K31/557 , A61K31/5575 , A61K45/06 , G01N33/88 , A61K2300/00
摘要： The present invention relates to methods for stimulating bone formation in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype agonist.
摘要翻译： 本发明涉及用于刺激哺乳动物骨形成的方法，包括向有需要的哺乳动物施用治疗有效量的EP> 4受体亚型激动剂。
-
公开(公告)号：EP0722462B1
公开(公告)日：2003-04-09
申请号：EP94928741.1
申请日：1994-10-03
发明人： ABRAMOVITZ, Mark , BOIE, Yves , GRYGORCZYK, Richard , METTERS, Kathleen , RUSHMORE, Thomas H. , SLIPETZ, Deborah M.
IPC分类号： C07K14/72
CPC分类号： C07K14/705 , A61K38/00 , C07K14/72
摘要： A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
-
3.发明公开COMBINATION THERAPY USING COX-2 SELECTIVE INHIBITOR AND THROMBOXANE INHIBITOR AND COMPOSITIONS THEREFOR 审中-公开组合制备血栓抑制剂和选择性COX-2抑制剂组成
公开(公告)号：EP1283723A2
公开(公告)日：2003-02-19
申请号：EP01933495.2
申请日：2001-05-14
CPC分类号： A61K45/06
摘要： The present invention provides a method for the treatment or prophylaxis of COX-2 mediated conditions in patients who are at risk of developing thromboembolic events which comprises administering to said patient a therapeutically or prophylactically effective amount of a COX-2 selective inhibitor and a cardiovascular protective amount of a thromboxane inhibitor, as well as compositions therefor.
-
4.发明公开COMBINATION PRODUCT COMPRISING AN E-TYPE PROSTAGLANDIN LIGAND AND A COX-2 SELECTIVE INHIBITOR AND METHODS OF USE 审中-公开复合制剂，前列腺素E-配体和供其使用选择性COX-2抑制剂和方法组成
公开(公告)号：EP1123091A1
公开(公告)日：2001-08-16
申请号：EP99952176.8
申请日：1999-10-21
CPC分类号： A61K45/06 , A61K31/365 , A61K31/18 , A61K2300/00
摘要： A pharmaceutical composition is disclosed which is comprised of an E-type prostaglandin ligand and a COX-2 selective inhibiting compound, in combination with a pharmaceutically acceptable carrier. Methods of treatment are also disclosed wherein an E-type prostaglandin ligand and a COX-2 selective inhibiting compound are administered in an amount that is effective to treat or prevent an E-type prostaglandin and/or COX-2 mediated disease or condition.
-
公开(公告)号：EP1148877A1
公开(公告)日：2001-10-31
申请号：EP99970321.8
申请日：1999-10-12
发明人： HARADA, Shun-Ichi , MACHWATE, Mohamed , RODAN, Gideon, A. , LABELLE, Marc , METTERS, Kathleen , YOUNG, Robert, N.
IPC分类号： A61K31/41 , A61K31/66 , A61K31/415 , A61K31/675
CPC分类号： G01N33/88 , A61K31/00 , A61K31/4196 , A61K31/66 , A61K45/06 , G01N2500/04 , G01N2500/10 , A61K2300/00
摘要： The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
-
-
-
-
搜索结果
5 条记录 (耗时 0.011 秒)
